Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study

Kosh Agarwal, Marı́a Buti, Florian van Bömmel, Pietro Lampertico, Ewa Janczewska, Marc Bourlière, Thomas Vanwolleghem, Oliver Lenz, Thierry Verbinnen, Thomas N. Kakuda, Cristina Mayer, John Jerzorwski, Maria Beumont-Mauviel, Ronald Kalmeijer, Michael Biermer, Isabelle Lonjon‐Domanec